Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
"On January 10, 2024, the Competition and Markets Authority issued an update regarding NHS set to benefit from £23 million following CMA pharma probe. The investigation focused on intravenous iron treatments, and Vifor Pharma agreed to address competition concerns by making a payment of £23 million and introducing measures to prevent misinformation about rival treatment Monofer."
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
